Latest liver cancer Stories
WOONSOCKET, R.I., May 16, 2013 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) is pleased to announce the filing of a U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma. Hepatocellular carcinoma is the most common form of primary liver cancer,...
WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga(®) (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC) who have progressed on Nexavar(®) (sorafenib) tablets, an anticancer medicine for the treatment of patients with...
CDC estimates “silent killer” affects five million Americans. Camden, NJ (PRWEB) May 13, 2013 When 57-year-old Vineland resident Rafael Roman was hospitalized at a South Jersey medical center with liver failure one year ago, his doctor told him there was nothing that could be done for him. “He told me I’d be lucky to make it to the end of the week,” says Roman, a father of five. “I said to him, ‘You know it’s Thursday, right?’” Fortunately,...
Regular exercise has been proven to reduce the chance of developing liver cancer in a world-first mice study that carries hope for patients at risk from hepatocellular carcinoma (HCC). The research announced at the International Liver Congress™ 2013 involved two groups of mice fed a control diet and a high fat diet then divided into separate exercise and sedentary groups. The exercise groups ran on a motorized treadmill for 60 minutes per day, five days a week. After 32 weeks of...
New data from two clinical trials presented today at the International Liver Congress™ 2013 demonstrate substantial improvements in the detection of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) using diagnostic urine tests. HCC is common throughout the world and most often develops as a late complication of chronic viral hepatitis or cirrhosis of any cause. The overall survival rate of HCC is poor and so screening for HCC offers the best hope for early detection,...
Research announced today at the International Liver CongressTM 2013 has revealed the deadly impact that alcohol and body weight have on liver disease. Women should forgo the wine and doughnuts after a new study found the harmful combination of high alcohol intake and high body mass index (BMI) causes an increased risk of chronic liver disease. The study analyzed a cohort of over 107,000 women to investigate how a female's weight and alcohol consumption affected their chances of suffering...
First randomized trial finds home-based health education most effective In the first study of its kind, lay health workers increased screening rates for hepatitis B virus (HBV) and knowledge about the disease among a group of Asian Americans, known as the Hmong, UC Davis researchers have found. The study appears online today in Cancer Epidemiology, Biomarkers & Prevention. Hmong Americans, who originate from the mountainous areas of Laos, are at elevated risk for chronic hepatitis B...
When standard treatment doesn't work or isn't possible A new minimally invasive tumor ablation technique is providing hope for liver cancer patients who can't undergo surgery or thermal ablation, a study shows. The study of 22 patients at the Universitatsklinikum Regensberg in Regensberg, Germany, found that irreversible electroporation (IRE) successfully destroyed tumor tissue in 70% of these patients. These patients were not responsive to conventional therapy or their tumor was in a...
Full range of equipment and software for the precision treatment of cancer exhibited at the Geneva Convention Center GENEVA, Switzerland, April 18, 2013 /PRNewswire/ -- Booths 5000/4700 - Varian Medical Systems (NYSE:VAR), the world leader in radiotherapy equipment and software, will demonstrate its full range of radiotherapy delivery systems and software at the 2(nd) ESTRO (European Society for Radiotherapy and Oncology) Forum, taking place April 19(th)-22(nd). The Varian booth will...
Bel Marra Health, who offers high-quality, specially formulated vitamins and nutritional supplements, is reporting on new research that says the value of liver cancer screening in patients with alcoholic cirrhosis might be questionable. Toronto, ON (PRWEB) April 06, 2013 Bel Marra Health, who offers high-quality, specially formulated vitamins and nutritional supplements, is reporting on new research that says the value of liver cancer screening in patients with alcoholic cirrhosis might...
